Alpha Centric Advisors LLC Aldeyra Therapeutics, Inc. Transaction History
Alpha Centric Advisors LLC
- $97.4 Million
- Q4 2024
A detailed history of Alpha Centric Advisors LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 46,913 shares of ALDX stock, worth $297,897. This represents 0.24% of its overall portfolio holdings.
Number of Shares
46,913Holding current value
$297,897% of portfolio
0.24%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
127Shares Held
37.6MCall Options Held
757KPut Options Held
539K-
Perceptive Advisors LLC New York, NY9.28MShares$58.9 Million1.54% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$34.8 Million17.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$23.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$23 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.47MShares$9.33 Million0.17% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $370M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...